PharmTech News

Articles

The agency is warning patients and healthcare providers about pre-filled pens falsely labeled as Ozempic.

EMA Warns About Falsified Ozempic Pens

The recommended medicines include treatments for Duchenne muscular dystrophy, relapsed or refractory multiple myeloma, hyperargininemia, invasive candidiasis, menopause symptoms, and diagnostic medicines for characterizing lesions.

EMA Recommends Seven Medicines for Approval in October

The agency recommended conditional marketing authorization for Elrexfio (elranatamab) as a monotherapy for adult patients with relapsed and refractory multiple myeloma.  

EMA Recommends Multiple Myeloma Treatment

Feliza Mirasol is the science editor for 

Salipro Biotech and Icosagen have entered into a multi-target collaboration to discover and characterize monoclonal antibodies.

Salipro Biotech and Icosagen to Collaborate on Antibody Discovery

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Janssen has requested an extension to the indication application of its fully-human, bispecific antibody treatment, Rybrevant (amivantamab). 

Janssen Seeks European Approval of Extended Indication for Rybrevant

Orakl Oncology has raised funds to develop its precision oncology platform and accelerate drug development.

Millions Raised for the Development of Precision Oncology Platform

Biosynth has further strengthened its peptide division with the acquisition of  Pepceuticals.

Biosynth Strengthens Position in Peptide Field through Pepceuticals Acquisition

The BioIndustry Association reports that with a strong foundation in research and development in mRNA the United Kingdom will be a major player in this rapidly growing industry.

UK Poised to Lead Global Delivery of Next-Gen mRNA Medicines

Under the partnership, Sartorius will leverage SPARTA Biodiscovery’s technology to accelerate development of nanoparticles used for drug delivery.

Sartorius and SPARTA Biodiscovery Partner on Novel Nanoparticle Analysis Platform 

With the two new GMP-grade mRNA manufacturing sites in Germany, MilliporeSigma can now offer fully integrated mRNA services.

PharmTech Europe News